Charles Darwin University

CDU eSpace
Institutional Repository

CDU Staff and Student only

Granucolocyte-Colony Stimulating Factor (G-CSF) as an adjunct to anitbiotics in the treatment of pneumonia in adults (Review)

Cheng, Allen C., Stephens, Dianne P. and Currie, Bart J. (2007). Granucolocyte-Colony Stimulating Factor (G-CSF) as an adjunct to anitbiotics in the treatment of pneumonia in adults (Review). Cochrane Database of Systematic Reviews,2007(2 - Article No. CD004400).

Document type: Journal Article
Citation counts: Altmetric Score Altmetric Score is 3
Google Scholar Search Google Scholar
Attached Files (Some files may be inaccessible until you login with your CDU eSpace credentials)
Name Description MIMEType Size Downloads
Download this reading Cheng_2590.pdf Published version application/pdf 213.03KB 245
Reading the attached file works best in Firefox, Chrome and IE 9 or later.

Title Granucolocyte-Colony Stimulating Factor (G-CSF) as an adjunct to anitbiotics in the treatment of pneumonia in adults (Review)
Author Cheng, Allen C.
Stephens, Dianne P.
Currie, Bart J.
Journal Name Cochrane Database of Systematic Reviews
Publication Date 2007
Volume Number 2007
Issue Number 2 - Article No. CD004400
ISSN 1469-493X   (check CDU catalogue open catalogue search in new window)
Total Pages 16
Place of Publication United Kingdom
Publisher John Wiley & Sons Ltd.
HERDC Category C1 - Journal Article (DEST)
Abstract Background
Granulocyte colony stimulating factor (G-CSF) is a naturally-occurring cytokine that has been shown to increase neutrophil function and number. Exogenous administration of recombinant G-CSF (filgrastim, pegfilgrastim or lenograstim) has found extensive use in the treatment of febrile neutropenia, but its role in the treatment of infection in non-neutropenic hosts is less well defined.


We explored the role of G-CSF as an adjunct to antibiotics in the treatment of pneumonia in non-neutropenic adults.

Search methods

For this updated review we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2006, issue 4); MEDLINE (1950 to January 2007); EMBASE (1988 to January 2007); and online databases of clinical trials (, updated 10 November, 2006).

Selection criteria

We considered randomized controlled trials (RCTs) which included hospitalized adult patients with either community-acquired pneumonia or hospital-acquired pneumonia.

Data collection and analysis

Two review authors independently extracted data and assessed trial quality. The primary outcome measure was 28-day mortality. Secondary outcome measures included other markers of mortality as well as markers of adverse events, including organ dysfunction. An assessment of methodological quality was made for each study.

Main results

Six studies with a total of 2018 people were identified. G-CSF use appeared to be safe with no increase in the incidence of total serious adverse events (pooled odds ratio (OR) 0.91; 95% confidence interval (CI): 0.73 to 1.14) or organ dysfunction. However, the use of G-CSF was not associated with improved 28-day mortality (pooled OR 0.81; 95% CI: 0.52 to 1.27).

Authors' conclusions

There is no current evidence supporting the routine use of G-CSF in the treatment of pneumonia. Studies in which G-CSF is administered prophylactically or earlier in therapy may be of interest.
DOI   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)

© copyright

Every reasonable effort has been made to ensure that permission has been obtained for items included in CDU eSpace. If you believe that your rights have been infringed by this repository, please contact

Version Filter Type
Access Statistics: 66 Abstract Views, 246 File Downloads  -  Detailed Statistics
Created: Fri, 12 Sep 2008, 08:35:25 CST by Administrator